|Event:||Jefferies 2012 Global Healthcare Conference|
|Presenter:||Ron Squarer, Chief Executive Officer|
|Date:||Wednesday, June 6, 2012|
|Time:||2:30 p.m. Eastern Time|
The Loxo phase II 'basket' study of larotrectinib is expected to complete patient enrollment in early 2017 and report results in the second half of the year.
Alaska Air is 'among the best,' says Jim Cramer; he also likes Southwest.
How did these technology stocks suddenly get their groove back? asks Jim Cramer.
The market isn't buying that Trump is bad for business